GlyCaBiota · Doctoral Training Network on Glycan–Cancer–Microbiota Interactions for Therapeutic and Diagnostic Innovation in Colorectal cancer

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Colorectal cancer (CRC) remains a major global health challenge, and increasing evidence shows that gut microbiota plays a decisive role in tumour progression and immune escape. Yet, the molecular rules governing communication between tumour cells, microbes and the immune system remain unknown. GlyCaBiota DN addresses this critical gap by focusing on how tumour and microbial glycans and proteins that recognize them shape CRC biology. Our innovative programme places glycan-mediated interactions at the core of the tumour–microbiota–immune axis, enabling the rational development of next-generation diagnostic and therapeutic strategies. By combining structural, cellular and computational approaches, GlyCaBiota will decode the molecular mechanisms driving microbial colonisation, immune modulation and CRC progression. Our consortium brings together leading experts in glycoscience, microbiology, cancer biology and immunology, structural biology, bioinformatics and translational research. With nine academic and five industrial partners, one oncology center and an international network, GlyCaBiota provides complementary expertise, unique tools and clinical connections to train 15 doctoral candidates (DCs). The combination of excellent interdisciplinary science, industry know-how and clinical perspective covers the entire pipeline from fundamental discoveries to innovative solutions. DCs will gain cutting-edge scientific and transferable skills, positioning them for impactful careers across academia, industry and healthcare. GlyCaBiota will create a critical mass of researchers capable of integrating glycoscience and microbiome research to tackle key challenges in CRC. By deciphering glycan-mediated interactions, GlyCaBiota will expand fundamental knowledge and strengthen European innovation capacity, enabling future development of precision diagnostics and therapeutic strategies for CRC.

Original text from CORDIS.

Participants

• UNIVERSIDADE NOVA DE LISBOA · LisboaCoordinatorPortugal
• ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
• ADAPTAM THERAPEUTICS SL · SAN SEBASTIANSpain
• ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS · DERIO VIZCAYASpain
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisFrance
• Canadian Glycomics Network · EdmontonCity levelCanada
• GLYCODISPLAY APS · KobehavnDenmark
• GlycoTherapeutics B.V. · NijmegenCity levelNetherlands
• IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE · LondonUnited Kingdom
• INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE · PortoPortugal
• KOBENHAVNS UNIVERSITET · KOBENHAVNDenmark
• LUDGER LIMITED · AbingdonUnited Kingdom
• NZYTECH LDA · LisboaCity levelPortugal
• QUADRAM INSTITUTE BIOSCIENCE · NorwichUnited Kingdom
• SIB SWISS INSTITUTE OF BIOINFORMATICS · GenfSwitzerland
• STICHTING RADBOUD UNIVERSITEIT · NijmegenNetherlands
• UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA · LeioaSpain
• UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II · NapoliItaly
• UNIVERSITE GRENOBLE ALPES · GrenobleFrance
• UNIVERSITY OF EAST ANGLIA · NorwichUnited Kingdom

Links

• View on CORDIS
• DOI: 10.3030/101312796